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A recombinant targeting bifunctional hirudin was expressed in the yeast Pichia pastoris. In order to 
decrease the side effects of hirudin and increase its activity to prevent arterial thrombus, we fused a 
factor Xa (FXa) recognition sequence into N’ of hirudin, while maintaining the activity of natural 
hirudin. In addition, an Arg-Gly-Asp (RGD) sequence was fused into appropriate genetic locus of 
hirudin. Furthermore, we added a 9 × His - Tag to make its separation and purification conveniently. 
The recombination hirudin gene was successfully cloned and ligated into the P. pastoris vector 
pPIC9K to form an expression vector, which was transferred into P. pastoris GS115. A transformant 
strain was selected and expressed efficiently in suitable conditions. Then, the fusion protein was 
purified by affinity chromatography. Through anti-thrombin activity analysis and anti-platelet 
aggregation activity analysis, we found that the anti-thrombin activity of the fusion protein did not 
change comparing with the natural hirudin, whereas its anti-platelet capability was enhanced. 
 





Cardiocerebral vascular diseases lead to about 17 
million deaths every year around the world. Currently, 
scientists are focusing more than ever on discovering 
effective anti-thrombin drugs (Breddin, 2002). Hirudin is 
a potent thrombin inhibitor, which has a molecular 
weight of 7,000 Da secreted from salivary glands of 
Hirudo medicinalis. Thrombin converts fibrinogen to 
fibrin, which is the final step in the process of 
hemostatic clot formation. Hirudin binds to the active 
site of thrombin, preventing thrombin’s interaction with 
fibrinogen, thereby blocks subsequent blood coagu- 
lation (Markwardt, 1989; Rosenfeld et al., 1996). As an 
effective drug to prevent thrombus, hirudin has various 
advantages, such as the stable and sustained anti- 
thrombus activity, the specific thrombin inhibition 
activity, rare side effects, teeny antigenicity, little toxicity 
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heparin, hirudin exhibits significant bleeding side 
effects. Even worse, there are rare antagonists in 
bleeding induced by hirudin. Furthermore, hirudin is 
only effective in phlebothrombosis but not in arterioth- 
romobosis (Breddin, 2002). 
In order to overcome its side effects and to increase 
its activity to prevent arteriothromobosis, we fused a 
FXa recognition sequence into N-terminal’ of hirudin to 
minimize the effect of bleeding through elevating of its 
specific targeting while maintaining the activity of 
natural hirudin (Harker et al., 1997; Mann, 1994; Niu et 
al., 2006). In addition, we fused an Arg-Gly-Asp (RGD) 
sequence into appropriate genetic locus of hirudin to 
elevate its activity of platelet aggregation inhibition, 
which would greatly increase its activity of preventing 
arterial thrombus formation (Bennett, 2001; Smith et al., 
1995; Zhang et al., 2006; Zhou et al., 2001; Zokai et al., 
2001). Furthermore, we added a 9×His-Tag to make its 
separation and purification conveniently, which makes 
the large amount of fusion hirudin protein production 
available. The recombination hirudin gene was 
successfully synthesized and ligated into  the  Pichia 




Table 1. Sequences of primers. 
 
Primer Sequence 
Hv 1 5'-AAGGATCCGATGATGATGATAAGATTGAGGGTCGTGTTGTTTACACTGAT-3' 
Hv 2 5'-ACCCTCGCAAAGGCAAAGGTTTTGACCAGACTCGGTGCAATCAGTGTAAACAAC-3' 
Hv 3 5'-TGCCTTTGCGAGGGTTCCAACGTTTGCGGTCAAGGTAACAAGTGCATTCTTGGT-3' 
Hv 4 5'-AACGCATTGGTTCTTATCACCACGACCAAGAATGCACTT-3' 
Hv 5 5'-AAGAACCAATGCGTTACTGGTGAAGGTACTCCTAAGCCTCAATCTCATAACGATGGTG-3' 
Hv 6 5'-TTGGATCCTTATTGAAGGTAATCCTCAGGAATTTCTTCGAAGTCACCATCGTTATGAG-3' 
A 5'-CGGAATTCCACCACCACCACCACCACCACCACCACCACGGATCCGATGATGATGATAA-3' 
B 5'-TTGCGGCCGCTTATTGAAGGTAATCCTCAG-3' 
pPIC9K 1 5'-TACTATTGCCAGCATTGCTGC-3’ 




pastoris vector pPIC9K to form an expression vector, 
which was transferred into P. pastoris GS115 suc- 
cessfully as evidence by the functional assay with 




MATERIALS AND METHODS 
 
Enzymes, cell strain and plasmid 
 
Escherichia coli JM 109 strains, the plasmid vector pMD18-T, 
restrictive endonucleases, Taq DNA polymerase, T4 DNA ligase, 
were purchased from TaKaRa biotechnology. The plasmid 
expression vector pPIC9K and P. pastoris expression host strain 
GS115 were purchased from invitrogen. The standard mini plasmid 
Prep kit and the DNA gel extraction kit were purchased from Bioteke. 
BCA protein assay kit was purchased from Pierce. The natural 
hirudin, the fibrinogen and the thrombin were purchased from sigma. 
The enterokinase (EK) was purchased from Kerun biopharma- 
ceutical R&D Co. Ltd (Chongqing, China). The factor Xa (FXa) was 
purchased from Promega. 
 
 
The design of primers 
 
According to the requirement of experiments, 6 primers, Hv1, Hv2, 
Hv3, Hv4, Hv5 and Hv6, were designed for the combination of the 
DNA sequence of a fusion protein, named as r-HV (fusion hirudin 
linked with FXa recognition sequence and RGD sequence). 
Primer A and B were designed for ligating the gene fragment of 
the recombinant protein r-HV into the expression vector pPIC9K 
and pPIC9K1 and pPIC9K2 were designed for the identification of 




Synthesis of the fusion protein gene 
 
The DNA sequence of our fusion protein was achieved by 3 
rounds of PCR (Figure 1). The first round PCR reaction systems: 
10 × PCR buffer 5.0 ul, MgCl2 (25 mM) 3.0 ul, dNTPs mixture (10 
mM) 1.0 ul, rTaq (5 U/ul) 0.5 ul, Primer Hv1/ Hv3/ Hv5 (10 uM) 1.0 ul, 
Primer Hv2/ Hv4/ Hv6 (10 uM) 1.0 ul, add ddH2O to 50.0 ul. PCR 
reaction conditions: 94°C 5min 1cycle; 94°C 30s, 55°C 30s, 72°C 
30s 35 cycles; 72°C 10min. 
After the first round PCR, 3 DNA fragments including product 1, 
product 2 and product 3 can be obtained respectively. Then with 
primers Hv1 and Hv4, the second round PCR was carried out and 
yielded product A by using the product 1 and product 2 as templates. 
At the same time, another PCR product B was amplified by using the 
product 2 and product 3 as templates, with primers Hv3 and Hv6. 
Finally, the third round PCR was carried out and the fusion protein 
gene r-HV was acquired with primers Hv1 and Hv6 and the product 
A and product B as templates. The second and third round PCR 
reaction conditions are the same as the first round PCR. Then, 
the r-HV was purified and sub-cloned into pMD18-T to yield 
recombinant plasmid pMD18-T-r-HV.  
 
 
Construction of expression vector pPIC9K-r-HV 
 
The r-HV gene fragment was amplified from plasmid pMD18-T-r-HV 
with primer A and primer B. Primer A contains an EcoRI site and a 
9×His-Tag sequence. Primer B contains a NotI site to facilitate 
sub-clone. Digested with EcoRI and NotI, the above PCR product 
was ligated into pPIC9K to construct the expression vector 
pPIC9K-r-HV. The recombinant was identified by restriction 
enzyme analysis and sequencing (Invitrogen in Shanghai). 
 
 
Expression and purification of fusion protein r-HV   
 
The pPIC9K-r-HV plasmid was linearized with SalI and was 
electroporated into P. pastoris strain GS115 with the condition of 
1500 V, 25 F and 400 , with 1 mL pre-cooled 1 mol/L D-sorbitol. 
The cells were plated onto YPD medium(1 yeast extract, 2 
peptone, 2 dextrose, 2% agar) containing 0, 1.0, and 2.0 mg/ml 
G418. The Mut+ and Muts phenotypes of the transformants were 
evaluated by spotting them on the MD plates (1.34% YNB, 2% 
dextrose, 4 ×10-5% D-biotin, 1.5% agar) and the MM plates 
(1.34% YNB, 0.5% methanol, 4 ×10-5% D-biotin, 1.5% agar). The 
positive transformants harboring r-HV were identified by PCR 
and grown overnight in 5 ml BMGY medium (1% yeast extract, 
2% tryptone, 100 mM phosphate potassium buffer, 1.34% YNB, 4 
× 10-5% D-biotin and 1% glycerol) at 30°C with shaking. The 
cultures were centrifuged and the cell pellets were resuspended 
in 1:10 the original volume in MM medium (1.34% YNB, 0.5% 
methanol, 4 × 10-5% D-biotin). After 2 days culturing under the 
conditions mentioned above, the expression of r-HV protein was 
induced with daily additions of 1.0% v/v methanol. Then the 
harvested supernatant was centrifuged at 4,000 g for 20 min and 
the interested protein was purified by affinity chromatography 
and analyzed by SDS–PAGE gel. 










Anti-thrombin activity analysis  
 
The anti-thrombin activity of the recombinant protein was evalua- 
ted with anti-thrombin titration method as previously described 
(Markwardt et al., 1970; Markwardt, 1994). Different concen- 
trations of samples were prepared. Then, direct titrations with 
thrombin were performed respectively, in a 37°C constant tempe- 
rature container. 
 
Anti-platelet aggregation activity analysis 
 
The anti-platelet aggregation activity was assayed by turbidity 
method as described previously (Imura et al., 1992). Venous 
blood was collected from healthy human donors, who didn’t take 
any drug 2 weeks before the donation. Blood samples were 
centrifuged at 950 rpm for 10 min or 2,000 rpm for 10 min at room 
temperature to obtain platelet rich plasma (PRP) or platelet poor 
plasma (PPP) respectively. Platelet aggregation was measured 
with multi-functional intelligence blood condense-meter of 
TYXN-96 series (Shanghai Research Institute of General Elec- 
tronics and Machinery). The r-HV was added into the cuvettes 
with PRP solution to with final concentration as 0.001 and 0.00015 
mg/ml respectively. After 15 min incubation at room temperature, 
5 ul ADP (final concentration: 5 uM) was added into cuvettes to 





Synthesis of the fusion protein gene r-HV 
 
In order to minimize the side effects of hirudin and to 
increase its activity to prevent arterial thrombus forma- 
tion, we designed 6 primers, Hv1, Hv2, Hv3, Hv4, Hv5 
and Hv6, for the combination of the nucleotide sequence 
of the fusion protein r-HV, which has specific targeting 
and anti-platelet aggregation activities without affecting 
natural hirudin activity. Through 3 rounds of PCR, the 
DNA fragment of the fusion protein r-HV was obtained. 
After subcloning the fragment and analyzing the nucle- 
otide sequence of the clone, one DNA fragment was 
obtained. The nucleotide sequence and the deduced 




Construction of expression vector pPIC9K-r-HV 
 
A 9×His sequence was fused into the 5’ terminal of r-HV 
gene by PCR, which would make the purification of 
r-HV protein conveniently. Digested with EcoRI/NotI, 
the fusion r-HV fragment was sub-cloned into the 
pPIC9K plasmid. Thus, the fusion protein expression 
cassette contains 9×His-tag, an EK recognition site, a 
FXa recognition site and the hirudin contained RGD 




Induced expression of r-HV in P. pastoris 
 
After transferring the expression plasmid into P. pastoris 
strain GS115 by electroporation, 5 positive trans- 
formants were selected and induced by methanol. After 
4 days culture, 1 ml expression supernatant was centri- 
fuged and analyzed by SDS–PAGE gel. A maximal yield 
of foreign protein was attained in the transformant 2 
(lane 2) (Figure 4) with 2 target bands, which might be 
resulted from the degradation of the recombinant 
protein because of the long inducing duration. 


















Figure 4. SDS-PAGE result of the induced 
products. Lanes 1-5: culture supernatant of 
corresponding transformants 1-5. Lane 0: empty 





Anti-thrombin activity analysis of the expression 
supernatant 
 
To confirm the expression efficiency of the target 
protein from the transformant 2 and to determine the 
optimal induction time, samples of the expression 
medium supernatants of the transformant 2, taken at 
various time points, were treated with ultrafiltration 
centrifugalization and digested by factor Xa (FXa), then 
the anti-thrombin activity at different induction time was 
measured with anti-thrombin titration by the method of  
 
 
Figure 5. The anti-thrombin activity analysis of products 
after methanol inducement. Results represent the mean 




Markwardt et al. (1970, 1994). During induction, the 
anti-thrombin activity of the recombinant protein 
increased to 280 ATU/ml in a time dependent manner 
within 48 h (Figure 5) which implies that the optimized 
inducing time of the transformants was 48 h. Longer 
induction might result in the lose of anti-thrombin 
activity of the target protein, as evidence by the result 
from SDS-PAGE (Figure 4). 
 
 
Purification and SDS-PAGE analysis of recombinant 
protein 
 
The recombinant strain was concentrated by 10-fold 
ultrafiltration centrifugation. Then it was purified 
through affinity columns with AKTA and  HiTrap™ pre-  















Figure 6. SDS-PAGE analysis of the purified products. 
Lane 0: total protein without purification. Lane 0’: product 
purified through affinity columns without affinity adsorption. 
Lane 1-4: eluted products at various time intervals. Lane M: 




packed columns (Pharmacia). The purified recombinant 
protein was analyzed by SDS–PAGE (Figure 6). A 
single 15 kDa protein band about 15kDa molecular 
weight was obtained at propriety proper elution time 
(lane 3). Because hirudin is a small acidic protein, 
although the theoretical molecular weight of the 
recombinant protein should be 9.6 kDa, it may be less 
negatively charged in SDS-PAGE and shows low 
mobility, which is might be responsible for lower motility 
and the molecular weight increase (Bennett, 2001). The 
BCA protein concentration assay showed that the total 
protein level was 1.54 mg/ml and the interest r-HV 
protein level was 23.1 mg/L, which implied higher 
efficiency than other recombinant hirudin expression 
systems (Bar-Shavit et al., 1989). 
 
 
Western blotting analysis of purified recombinant 
protein 
 
As the target protein contains a 9×His-Tag recognition 
sequence in its N terminal, we analyzed the purified 
recombinant protein by western blotting with anti-his 
antibody (Figure 7). The western blotting showed that the 
expression of target protein was undetectable before 
methanol induction (lane 0). A single target protein band 
was observed in the expression supernatant after 
ultrafiltration centrifugation and affinity chromatography. 
 
 
Anti-thrombin activity assays 
 
As the expression protein has an EK and a FXa recog- 
nition sequence in its N terminal, EK and FXa have been 
selected to digest the purified recombinant protein. If 
digested with EK, one fusion protein with a FXa 











Figure 7. Western-blot identification of the purified 
products.Lane 1: product purified by ultrafiltration 
centrifugation and affinity chromatography from expression 
supernatant after 2 days induction culture. Lane 2: product 
purified by ultrafiltration centrifugation from expression 
supernatant after 2 days induction culture. Lane 0: the 
control group without induction expression. Lane M: 




digested by FXa, another protein without a FXa 
recognition sequence in its N terminal was obtained. The 
anti-thrombin activities of proteins, those before and 
after digestion by EK and FXa, were measured with 
anti-thrombin titration by the method of Markwardt et al. 
(1970, 1994). The results were shown in Table 2. 
The recombinant protein, which contains a 9×His-Tag, 
an EK and an FXa recognition sequence in its N terminal, 
had low anti-thrombin activity, which indicated that the 
hirudin would lose anti-thrombin activity with long amino 
acid sequences in its N terminal. The recombinant 
protein with only an FXa recognition sequence in its N 
terminal had a partial anti-thrombin activity, which might 
be attributed to that the FXa recognition sequence has 
only 4 amino acid residues and could not completely 
inhibit the anti-thrombin activity. The protein digested 
by FXa had a similar anti-thrombin activity with natural 
hirudin. 
In Table 2, sample A was the recombinant protein 
without digestion. Sample B was the protein digested 
by EK, which was the interest protein. Sample C was 
the protein digested by FXa, which was the bifunctional 
hirudin after activating by digested in vivo conditions. 
Sample D was the standard hirudin (0.1 mg /ml). 
 
 
Anti-platelet aggregative activity assays 
 
The anti-platelet aggregative activity was assayed by 
turbidity method. The inhibition of platelet aggregation 
was calculated by the following formula:  
The inhibition of platelet aggregation (%) = (platelet 
aggregation of the control group%-the recombinant 
protein-induced platelet aggregation %)/platelet aggre- 
gation of the control group% ×100% (Table 3).  




Table 2. Anti-thrombin activities analysis of fusion proteins. 
 
Assay A B C D 
Anti-thrombin activity (ATU/ml) 280 8040 16760 1190 















Platelet aggregation PAG(M) 92.7% 94.2% 74.7% 81.1% 




The results indicated that the fusion protein, FXa- 
RGD–HV, had high anti-platelet aggregative activity. 
With physiological saline as control, the inhibition of 
platelet aggregation (%) of FXa-RGD–HV at the follow- 
ing concentrations, 0.001 and 0.00015 mg/ml, were 





Research in the cardiocerebral vascular diseases has 
made great progress, especially in the development of 
protein, peptide, or small molecules to inhibit blood 
coagulation proteases (Dodt et al., 1984; Seemmuller et 
al., 1986). Hirudin is a natural potent thrombin inhibitor, 
which can hold back the formation of fibrins in the 
coagulation pathway. At present, it has been studied 
extensively as an anticoagulant and should lead to 
targeted approaches to anticoagulant therapies 
(Rosenfeld et al., 1996). 
In this paper, we showed the synthesis procedures of 
a recombinant targeting bifunctional hirudin and an 
novel expression vector, pPIC9K-r-HV, which can be 
transferred into P. pastoris GS115 and the constructed 
hirudin was properly expressed and secreted into 
culture supernatants as a soluble protein. The 
expression level of the recombinant protein could attain 
23.1mg/L level. In the meanwhile, the optimal 
conditions for expression were determined. The 
anti-thrombin activity and anti-platelet aggregation 
activity of recombinant hirudin were analyzed in vitro.  
Although the expression level of the fusion protein is 
higher than other recombinant hirudin expression 
systems (Bar-Shavit et al., 1989), the yield should be 
promoted further before the clinical use of this recom- 
binant protein. So, we would continue to select multiple 
copy transformants and optimize culture conditions. In 
addition, in vivo animal experiment study should be 
performed in the future for confirming the targeting 
activity and bifunction of the recombinant hirudin further. 
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